Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan cilexetil + amlodipine besilate
- Development stage
- Phase 4
- Lead developer
- Cardiotech Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aracure-A is a fixed-dose combination of candesartan cilexetil, an angiotensin II receptor antagonist, and amlodipine besilate, a dihydropyridine calcium channel blocker. It is marketed by Cardiotech Pharmaceutical in the Dominican Republic for the treatment of arterial hypertension and heart failure. Candesartan cilexetil acts as a prodrug that is rapidly hydrolyzed to candesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. Amlodipine besilate inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation. Together, these complementary mechanisms provide synergistic blood pressure reduction and cardiovascular protection.
- Brand names
- Aracure-A
- Other names
- amlodipine besilate + candesartan cilexetilamlodipine besylate + candesartan cilexetilcandesartan cilexetil + amlodipinecandesartan cilexetil/amlodipine besilatecandesartan cilexetil/amlodipine besylatecandesartan/amlodipine
02
Targets
ACE (Angiotensin Converting Enzyme)AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)MMP3 (Matrix metalloproteinase-3)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)REN (Renin)CaV3 (Caveolin-3)TGFBR (TGF-beta receptor)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on candesartan cilexetil + amlodipine besilate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan cilexetil + amlodipine besilate.